RxDoctor Payments Data

Katherine Dyer, PA

Surgical · Charlotte, NCNPI 1417363623

Payments from drug & device makers

What this record shows

This record is dominated by food and beverage: $1,676 of the $1,876 with a category attached, or 89.3%. 21 manufacturers reported payments, led by Astellas Pharma US Inc at 26.8% of the total. Reporting peaked in 2023 at $1,212 and has fallen 91.5% since, to $103 in 2025.

$1,876in general payments, 2019–2025

Across 73 payments — averaging $25.70 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Astellas Pharma US Inc$502
  • Sumitomo Pharma America, Inc.$223
  • Convatec Inc.$189
  • Endo Pharmaceuticals Inc.$164
  • Procept Biorobotics Corporation$148
  • Urogen Pharma, Inc.$136
  • plus $514 from 15 others

What the payments were for

  • Food & beverage$1,67689%
  • Education$20011%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,876 in reported general payments places this provider in the 85th percentile of 248 surgical providers in North Carolina.

See all surgical providers in North Carolina

Medicare billing

Part B allowed, 2024
$27,715
Medicare patients
208
Services billed
729

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
GemtesaVibegron61$51,441
MyrbetriqMirabegron44$20,920
ElmironPentosan Polysulfate Sodium12$14,156
Tamsulosin Hcl208$2,043
Finasteride162$1,963
Estradiol12$608
Methenamine Hippurate13$572
NitrofurantoinNitrofurantoin Macrocrystal14$411
Ciprofloxacin Hcl33$373
Oxybutynin Chloride17$326
Cephalexin25$318
Oxybutynin Chloride ErOxybutynin Chloride36$245
Testosterone Cypionate12$190
Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav21$157
Oxycodone Hcl26$127

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Sumitomo Pharma America, Inc.Gemtesa$223$51,44161 claims
Astellas Pharma US IncMyrbetriq$502$20,92044 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 248 surgical providers in North Carolina.

Other surgical in Charlotte

See the full list for North Carolina

Where these figures come from

Is this you, or does something look wrong? →